cst, page-2

recent rises due to speculation around FDA approval for Quantiferon Gold and Japanese approval. Both are due in June and both are expected to be fulfilled. Cellestis are the sole player in a world market and their prospects in Japan are enormous given the incidence of TB in Japan and the uselessness of the Mantoux test. The Japanese studies will open the door for large institutions to validate the use of Quantiferon Gold in their hospitals so the short term upside is very positive. A sole player in the world market.........